These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 30716352)

  • 1. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed/refractory acute lymphoblastic leukemia.
    Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapies in Acute Lymphoblastic Leukemia.
    Phelan KW; Advani AS
    Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
    Gökbuget N
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immunotherapies in lymphoid malignancies.
    Batlevi CL; Matsuki E; Brentjens RJ; Younes A
    Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Acute Lymphoblastic Leukemia.
    Rheingold SR
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469898
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
    Patel J; Gao X; Wang H
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of cellular immunotherapy for childhood leukemia.
    Bonifant CL; Tasian SK
    Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults.
    Kimble EL; Cassaday RD
    Leuk Lymphoma; 2021 Dec; 62(14):3333-3347. PubMed ID: 34402732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.
    Lussana F; Gritti G; Rambaldi A
    J Clin Oncol; 2021 Feb; 39(5):444-455. PubMed ID: 33434063
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.
    Molina JC; Carraway HE
    Curr Treat Options Oncol; 2024 Aug; 25(8):993-1010. PubMed ID: 38916714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.